2/3 14:48 af HyaTror der bliver laver bear raid på dndn idag - er kommet en rapport der siger at de tror provenge skal i panel meeting igen MEN
2/3 14:49 af Hyader er jo en SPA (forhåndsgodkendelse hvis stoffet når de resultater) der er bevist - så jeg tror det er en købschanche
2/3 14:49 af Hyafordi godkendelsen snart kommer og der er mange shorts i aktien
Jeg ahr tidligere skrevet stolpe op og ned omkring dndn og de grove manipulationer der foregår i aktien IDAG er ingen undtagelse
selvom der har været pause et stykke tid!
så det er lærerigt at følge casen selvom man ikke ejer aktien!
jeg er selv LONG inde -
Kh Hya
2/3 14:49 af Hyader er jo en SPA (forhåndsgodkendelse hvis stoffet når de resultater) der er bevist - så jeg tror det er en købschanche
2/3 14:49 af Hyafordi godkendelsen snart kommer og der er mange shorts i aktien
Jeg ahr tidligere skrevet stolpe op og ned omkring dndn og de grove manipulationer der foregår i aktien IDAG er ingen undtagelse
selvom der har været pause et stykke tid!
så det er lærerigt at følge casen selvom man ikke ejer aktien!
jeg er selv LONG inde -
Kh Hya
2/3 2010 20:47 1970 0
26601 Godt med nyheder i dag - her en med kurstarget på 50.
http://www.reuters.com/article/idCNN0216221720100302?rpc=44
UPDATE 2-US FDA sees no public hearing for Dendreon vaccine
No advisory meeting planned-FDA spokeswoman
* Dendreon shares gain 6.5 percent (Adds analyst comment, details on study, updates shares)
By Susan Heavey
WASHINGTON, March 2 (Reuters) - The U.S. Food and Drug Administration is not planning to seek advice from its outside advisers over Dendreon Corp's (DNDN.O) experimental prostate cancer vaccine, fueling investor speculation about the product and sending company shares higher.
"There is not going to be an advisory committee meeting," FDA spokeswoman Shelly Burgess said on Tuesday.
The vaccine, Provenge, would be the first cancer vaccine aimed at treating a condition, rather than preventing a disease as traditional vaccines do.
The closely watched product could be a blockbuster for the biotech company, which has said it would ramp up production to handle an expected $1.2 billion to $2.5 billion of annual sales by late 2011.
The company's shares had fallen over speculation that Provenge might have to face public scrutiny at an FDA advisory panel but later recovered to trade up as much as 8.5 percent.
The FDA often seeks advice on whether to approve products from its panels of outside experts and usually, but not always, follows their recommendations.
Roth Capital Partners analyst Joseph Pantginis, in a note issued before the FDA said it would not convene a panel, said he expected Provenge to win the agency's clearance. He pointed to positive results released in April from a study called Impact.
"We believe Provenge will be approved on or about" May 1, the FDA's target date for a decision, Pantginis said. He reiterated his "buy" rating on Dendreon shares and a $50 price target.
Last April, data from the 512-patient Impact study showed the vaccine improved three-year survival of men with advanced prostate cancer by 38 percent compared with a placebo.
Dendreon shares were up 6.5 percent at $34.62 in midday trading on the Nasdaq. (Additional reporting by Esha Dey in Bangalore) (Reporting by Susan Heavey and Lisa Richwine; Editing by Robert MacMillan and Steve Orlofsky)
http://www.reuters.com/article/idCNN0216221720100302?rpc=44
UPDATE 2-US FDA sees no public hearing for Dendreon vaccine
No advisory meeting planned-FDA spokeswoman
* Dendreon shares gain 6.5 percent (Adds analyst comment, details on study, updates shares)
By Susan Heavey
WASHINGTON, March 2 (Reuters) - The U.S. Food and Drug Administration is not planning to seek advice from its outside advisers over Dendreon Corp's (DNDN.O) experimental prostate cancer vaccine, fueling investor speculation about the product and sending company shares higher.
"There is not going to be an advisory committee meeting," FDA spokeswoman Shelly Burgess said on Tuesday.
The vaccine, Provenge, would be the first cancer vaccine aimed at treating a condition, rather than preventing a disease as traditional vaccines do.
The closely watched product could be a blockbuster for the biotech company, which has said it would ramp up production to handle an expected $1.2 billion to $2.5 billion of annual sales by late 2011.
The company's shares had fallen over speculation that Provenge might have to face public scrutiny at an FDA advisory panel but later recovered to trade up as much as 8.5 percent.
The FDA often seeks advice on whether to approve products from its panels of outside experts and usually, but not always, follows their recommendations.
Roth Capital Partners analyst Joseph Pantginis, in a note issued before the FDA said it would not convene a panel, said he expected Provenge to win the agency's clearance. He pointed to positive results released in April from a study called Impact.
"We believe Provenge will be approved on or about" May 1, the FDA's target date for a decision, Pantginis said. He reiterated his "buy" rating on Dendreon shares and a $50 price target.
Last April, data from the 512-patient Impact study showed the vaccine improved three-year survival of men with advanced prostate cancer by 38 percent compared with a placebo.
Dendreon shares were up 6.5 percent at $34.62 in midday trading on the Nasdaq. (Additional reporting by Esha Dey in Bangalore) (Reporting by Susan Heavey and Lisa Richwine; Editing by Robert MacMillan and Steve Orlofsky)
2/3 2010 20:52 1970 026602 og lidt om dagens kursudvikling:
http://www.cnbc.com/id/35671755/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo
Nuthin' Like A Little Dendreon Dendrama
Published: Tuesday, 2 Mar 2010 | 12:46 PM ET
By: Mike Huckman
CNBC Correspondent
I'm still decompressing from a very stressful morning.
Shares of Dendreon [DNDN 34.39 1.88 (+5.78%) ] fell around 10 percent before the market opened. And now, in regular trading, they're at a new intra-day high.
Here's what happened.
Dr. Elliot Favus emailed me a research note this morning. I'd never heard of him before. He was telling investors to sell DNDN because he claimed to have been in contact with doctors who told him they'd been invited by the FDA to sit on an advisory committee to review Dendreon's prostate cancer treatment Provenge.
So, why would that be a big deal?
Well, biotech investors don't necessarily like outside FDA panels. They usually translate into a delay on an FDA decision about whether to approve a drug and they increase the uncertainty about a drug's fate. The committees only make recommendations to the agency on what it should do. The FDA usually, but not always follows the advice of its expert panels. Veteran DNDN investors learned about that the hard way. A few years ago, an advisory committee recommended approval of Provenge. The stock soared. Then, the FDA shocked the Street and said, "No." The shares tanked.
I emailed Dr. Favus to find out a little bit about him and his research. I asked him to send me some of his previous research reports on DNDN, including his coverage initiation note. He got back to me quickly saying this was his first call on DNDN, that he doesn't do "passive, ongoing research," and that his relatively new boutique firm, bearing his name, focuses on providing "money making ideas and divergent information in the healthcare sector."
He boasts that since he started the company a little more than a year ago that he's written a dozen reports, 10 of them with "Sell" recommendations. Dr. Favus used to work at Lazard Capital Markets.
Anyway, the controversial call triggered a flurry of tweets in my Twitterverse and a selloff in the stock in the pre-market and shortly after the opening bell. But then the FDA took the rare step of publicly commenting on whether a product would go before an advisory committee. Bloomberg broke it, the stock suddenly did an about face and started trading at new highs.
My producer and I began frantically trying to confirm the story on our own. But lemme tell ya how difficult it was reaching the media relations folks at the agency. We repeatedly emailed and voicemailed them; called the main news media line at the FDA, sometimes got a live person, sometimes voicemail, were told the people we needed to talk to were in a meeting, and on and on. Argh!
I told the person on the other end of the line to get the person out of the meeting. This was urgent. I'm on deadline. No luck. Eventually, I got a call back from one point-person and my producer got patched through to another. Both of them confirmed the FDA will not convene another Provenege panel. I hung up, ran downstairs and jumped on the air.
After I caught my breath, I sent Dr. Favus a follow-up email. Did he still stand by his call? Were the doctors he cited misinformed? Did he care to comment on what the FDA said? I haven't heard back.
Meantime, the FDA is expected to make a decision on Provenge on or before May 1st, which is a Saturday, by the way.
http://www.cnbc.com/id/35671755/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahoo
Nuthin' Like A Little Dendreon Dendrama
Published: Tuesday, 2 Mar 2010 | 12:46 PM ET
By: Mike Huckman
CNBC Correspondent
I'm still decompressing from a very stressful morning.
Shares of Dendreon [DNDN 34.39 1.88 (+5.78%) ] fell around 10 percent before the market opened. And now, in regular trading, they're at a new intra-day high.
Here's what happened.
Dr. Elliot Favus emailed me a research note this morning. I'd never heard of him before. He was telling investors to sell DNDN because he claimed to have been in contact with doctors who told him they'd been invited by the FDA to sit on an advisory committee to review Dendreon's prostate cancer treatment Provenge.
So, why would that be a big deal?
Well, biotech investors don't necessarily like outside FDA panels. They usually translate into a delay on an FDA decision about whether to approve a drug and they increase the uncertainty about a drug's fate. The committees only make recommendations to the agency on what it should do. The FDA usually, but not always follows the advice of its expert panels. Veteran DNDN investors learned about that the hard way. A few years ago, an advisory committee recommended approval of Provenge. The stock soared. Then, the FDA shocked the Street and said, "No." The shares tanked.
I emailed Dr. Favus to find out a little bit about him and his research. I asked him to send me some of his previous research reports on DNDN, including his coverage initiation note. He got back to me quickly saying this was his first call on DNDN, that he doesn't do "passive, ongoing research," and that his relatively new boutique firm, bearing his name, focuses on providing "money making ideas and divergent information in the healthcare sector."
He boasts that since he started the company a little more than a year ago that he's written a dozen reports, 10 of them with "Sell" recommendations. Dr. Favus used to work at Lazard Capital Markets.
Anyway, the controversial call triggered a flurry of tweets in my Twitterverse and a selloff in the stock in the pre-market and shortly after the opening bell. But then the FDA took the rare step of publicly commenting on whether a product would go before an advisory committee. Bloomberg broke it, the stock suddenly did an about face and started trading at new highs.
My producer and I began frantically trying to confirm the story on our own. But lemme tell ya how difficult it was reaching the media relations folks at the agency. We repeatedly emailed and voicemailed them; called the main news media line at the FDA, sometimes got a live person, sometimes voicemail, were told the people we needed to talk to were in a meeting, and on and on. Argh!
I told the person on the other end of the line to get the person out of the meeting. This was urgent. I'm on deadline. No luck. Eventually, I got a call back from one point-person and my producer got patched through to another. Both of them confirmed the FDA will not convene another Provenege panel. I hung up, ran downstairs and jumped on the air.
After I caught my breath, I sent Dr. Favus a follow-up email. Did he still stand by his call? Were the doctors he cited misinformed? Did he care to comment on what the FDA said? I haven't heard back.
Meantime, the FDA is expected to make a decision on Provenge on or before May 1st, which is a Saturday, by the way.
Det er hverken 1 eller sidste gang det sker!
men dennegang var det bare så gennemskueligt
og mon ikke de fleste investore efterhånden er ved at have hård hun på albuerne, når de vælger at være long i DNDN -
jeg forventer bestemt at der frem til godkendelsen fortsat vil blive væsentlige forsøg på manipulationer
for det 1 fordi mange ligger short
og fordi det hele tiden ahr været en kamp mellem ny behandlingsmulighed kontra existerende behandlinger
så det eneste man selv kan gøre er at spille på sort eller rød - og så holde fast
selv er jeg jo long - og benytter de mærkelige kursfald til at øge,
og jeg har IKKE stoplos på mine positioner
hvis kursen så skulle stige explosivt meget på een gang af lige så uforklarlige årsager - så reducerer jeg ½ delen af min position,
så jeg kan genkøbe når de falder tilbage
1970 TAK for din opfølgning af mit indlæg med dokumentationen - det var jeg glad for, du gad
Hya
men dennegang var det bare så gennemskueligt
og mon ikke de fleste investore efterhånden er ved at have hård hun på albuerne, når de vælger at være long i DNDN -
jeg forventer bestemt at der frem til godkendelsen fortsat vil blive væsentlige forsøg på manipulationer
for det 1 fordi mange ligger short
og fordi det hele tiden ahr været en kamp mellem ny behandlingsmulighed kontra existerende behandlinger
så det eneste man selv kan gøre er at spille på sort eller rød - og så holde fast
selv er jeg jo long - og benytter de mærkelige kursfald til at øge,
og jeg har IKKE stoplos på mine positioner
hvis kursen så skulle stige explosivt meget på een gang af lige så uforklarlige årsager - så reducerer jeg ½ delen af min position,
så jeg kan genkøbe når de falder tilbage
1970 TAK for din opfølgning af mit indlæg med dokumentationen - det var jeg glad for, du gad
Hya
3/3 2010 15:43 Hya 026647 Dendreon Corporation has added a news release to its Investor Relations website.
Title: Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date(s): 3/3/2010 8:39:28 AM
For a complete listing of our news releases, please click here
SEATTLE, March 3, 2010 /PRNewswire via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following three investor conferences this month.
Cowen and Company 30th Annual Health Care Conference, Boston, MA Tuesday, March 9, 2010 4:30 p.m. ET ROTH 22nd Annual OC Growth Stock Conference, Dana Point, CA Wednesday, March 16, 2010 12:00 p.m. ET WBBA 10th Annual Life Science Innovation Northwest 2010, Seattle, WA Wednesday, March 16, 2010 12:55 p.m. ET
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
SOURCE Dendreon Corporation
Title: Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
Date(s): 3/3/2010 8:39:28 AM
For a complete listing of our news releases, please click here
SEATTLE, March 3, 2010 /PRNewswire via COMTEX/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following three investor conferences this month.
Cowen and Company 30th Annual Health Care Conference, Boston, MA Tuesday, March 9, 2010 4:30 p.m. ET ROTH 22nd Annual OC Growth Stock Conference, Dana Point, CA Wednesday, March 16, 2010 12:00 p.m. ET WBBA 10th Annual Life Science Innovation Northwest 2010, Seattle, WA Wednesday, March 16, 2010 12:55 p.m. ET
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.
SOURCE Dendreon Corporation
